Abstract

The use of anticoagulant therapy during pregnancy is challenging because of the potential for both fetal and maternal complications. This guideline focuses on the management of VTE and thrombophilia as well as the use of antithrombotic agents during pregnancy. The methods of this guideline follow the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. We recommend low-molecular-weight heparin for the prevention and treatment of VTE in pregnant women instead of unfractionated heparin (Grade 1B). For pregnant women with acute VTE, we suggest that anticoagulants be continued for at least 6 weeks postpartum (for a minimum duration of therapy of 3 months) compared with shorter durations of treatment (Grade 2C). For women who fulfill the laboratory criteria for antiphospholipid antibody (APLA) syndrome and meet the clinical APLA criteria based on a history of three or more pregnancy losses, we recommend antepartum administration of prophylactic or intermediate-dose unfractionated heparin or prophylactic low-molecular-weight heparin combined with low-dose aspirin (75-100 mg/d) over no treatment (Grade 1B). For women with inherited thrombophilia and a history of pregnancy complications, we suggest not to use antithrombotic prophylaxis (Grade 2C). For women with two or more miscarriages but without APLA or thrombophilia, we recommend against antithrombotic prophylaxis (Grade 1B). Most recommendations in this guideline are based on observational studies and extrapolation from other populations. There is an urgent need for appropriately designed studies in this population.

Keywords

MedicineAntithromboticThrombophiliaLow molecular weight heparinGuidelineAntiphospholipid syndromePregnancyThrombosisAnticoagulantHeparinIntensive care medicineObstetricsPediatricsSurgeryInternal medicine

MeSH Terms

AbortionSpontaneousAnticoagulantsAntiphospholipid SyndromeDose-Response RelationshipDrugEvidence-Based MedicineFemaleFibrinolytic AgentsHeparinHeparinLow-Molecular-WeightHumansPregnancyPregnancy ComplicationsCardiovascularRisk FactorsSecondary PreventionSocietiesMedicalThrombophiliaVenous Thromboembolism

Affiliated Institutions

Related Publications

Publication Info

Year
2012
Type
article
Volume
141
Issue
2
Pages
e691S-e736S
Citations
1461
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1461
OpenAlex
74
Influential
1169
CrossRef

Cite This

Shannon M. Bates, Ian A. Greer, Saskia Middeldorp et al. (2012). VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy. CHEST Journal , 141 (2) , e691S-e736S. https://doi.org/10.1378/chest.11-2300

Identifiers

DOI
10.1378/chest.11-2300
PMID
22315276
PMCID
PMC3278054

Data Quality

Data completeness: 86%